CA
MLYS icon

Clearstead Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Clearstead Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$298 Hold
11
– – ﹤0.01% 2148
2025
Q4 		$400 Buy
+11
New +$441 ﹤0.01% 2333

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Clearstead Advisors's MLYS Position: Q1 2026 in Review

Clearstead Advisors held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 11 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Clearstead Advisors first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $400 in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Clearstead Advisors held 11 shares of Mineralys Therapeutics worth $298 as of Q1 2026.
  • Clearstead Advisors left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #2148 holding.
  • Clearstead Advisors first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's Mineralys Therapeutics position peaked at $400 in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.